Stoev S - Search Results

1

Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G. Manning M, et al. Among authors: stoev s. J Neuroendocrinol. 2012 Apr;24(4):609-28. doi: 10.1111/j.1365-2826.2012.02303.x. J Neuroendocrinol. 2012. PMID: 22375852 Free PMC article. Review.

2

Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.

Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C. Manning M, et al. Among authors: stoev s. J Pept Sci. 2005 Oct;11(10):593-608. doi: 10.1002/psc.667. J Pept Sci. 2005. PMID: 15880385

3

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Manning M, et al. Among authors: stoev s. Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Prog Brain Res. 2008. PMID: 18655903 Review.

4

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

Manning M, Stoev S, Kolodziejczyk A, Klis WA, Kruszynski M, Misicka A, Olma A, Wo NC, Sawyer WH. Manning M, et al. Among authors: stoev s. J Med Chem. 1990 Nov;33(11):3079-86. doi: 10.1021/jm00173a027. J Med Chem. 1990. PMID: 2231609

5

Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.

Manning M, Cheng LL, Klis WA, Stoev S, Przybylski J, Bankowski K, Sawyer WH, Barberis C, Chan WY. Manning M, et al. Among authors: stoev s. Adv Exp Med Biol. 1995;395:559-83. Adv Exp Med Biol. 1995. PMID: 8714021 Review.

6

Discovery and design of novel vasopressin hypotensive peptide agonists.

Manning M, Stoev S, Cheng LL, Wo NC, Chan WY. Manning M, et al. Among authors: stoev s. J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):631-44. doi: 10.3109/10799899909036676. J Recept Signal Transduct Res. 1999. PMID: 10071789

7

Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.

Manning M, Stoev S, Bankowski K, Misicka A, Lammek B, Wo NC, Sawyer WH. Manning M, et al. Among authors: stoev s. J Med Chem. 1992 Jan 24;35(2):382-8. doi: 10.1021/jm00080a027. J Med Chem. 1992. PMID: 1531076

8

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T. Terrillon S, et al. Among authors: stoev s. J Med Chem. 2002 Jun 6;45(12):2579-88. doi: 10.1021/jm010526+. J Med Chem. 2002. PMID: 12036367

9

Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G. Cheng LL, et al. Among authors: stoev s. J Med Chem. 2004 Apr 22;47(9):2375-88. doi: 10.1021/jm030611c. J Med Chem. 2004. PMID: 15084136

10

Design and synthesis of potent, highly selective vasopressin hypotensive agonists.

Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH. Stoev S, et al. J Pept Sci. 2006 Sep;12(9):592-604. doi: 10.1002/psc.756. J Pept Sci. 2006. PMID: 16625682

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters